Facts and Hopes in Thrombolysis in Acute Myocardial Infarction

[1]  P. Walker,et al.  Induction of a sustained fibrinolytic response by BRL 26921 in vitro. , 1985, Thrombosis research.

[2]  C. Francis,et al.  Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. , 1985, Circulation.

[3]  J. Hoffmann,et al.  Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction. , 1985, Thrombosis research.

[4]  R. Hornung,et al.  Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. , 1985, British heart journal.

[5]  R. Erbel,et al.  Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction. , 1984, Journal of the American College of Cardiology.

[6]  R. Smith,et al.  Acyl-Enzymes as Thrombolytic Agents in Dog Models of Venous Thrombosis and Pulmonary Embolism , 1984, Thrombosis and Haemostasis.

[7]  A. Rae,et al.  Acylated Streptokinase – Plasminogen Complex in Patients with Acute Myocardial Infarction , 1984, Thrombosis and Haemostasis.

[8]  M. Verstraete,et al.  On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). , 1981, Thrombosis research.

[9]  R. Smith,et al.  Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy , 1981, Nature.

[10]  R. Norris,et al.  A new coronary prognostic index. , 1970, Lancet.

[11]  J. Mills,et al.  Proceedings of the British Cardiac Society Acute coronary thrombolysis with a single intracoronary injection of BRL 26921 , 2022 .